113 related articles for article (PubMed ID: 7711677)
1. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party.
Sweetenham JW; Pearce R; Philip T; Proctor SJ; Mandelli F; Colombat P; Goldstone AH
Bone Marrow Transplant; 1994 Dec; 14(6):981-7. PubMed ID: 7711677
[TBL] [Abstract][Full Text] [Related]
2. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
Philip T; Armitage JO; Spitzer G; Chauvin F; Jagannath S; Cahn JY; Colombat P; Goldstone AH; Gorin NC; Flesh M
N Engl J Med; 1987 Jun; 316(24):1493-8. PubMed ID: 3295541
[TBL] [Abstract][Full Text] [Related]
4. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
5. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
6. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Mendoza E; Territo M; Schiller G; Lill M; Kunkel L; Wolin M
Bone Marrow Transplant; 1995 Feb; 15(2):299-303. PubMed ID: 7773222
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
9. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
Stein RS; Greer JP; Goodman S; Brandt SJ; Morgan DS; Macon WR; McCurley TL; Wolff SN
Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.
de Kreuk M; Ossenkoppele GJ; Meijer CJ; Huijgens PC
Bone Marrow Transplant; 1996 Jun; 17(6):963-71. PubMed ID: 8807101
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.
Schimmer AD; Jamal S; Messner H; Keating A; Meharchand J; Huebsch L; Walker I; Benger A; Gluck S; Smith A
Bone Marrow Transplant; 2000 Oct; 26(8):859-64. PubMed ID: 11081385
[TBL] [Abstract][Full Text] [Related]
12. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
[TBL] [Abstract][Full Text] [Related]
15. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
16. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
17. Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.
Moreau P; LeTortorec S; Mahé MA; Mahé B; Moreau A; Bourdin S; Bulabois CE; Bureau B; Harousseau JL; Milpied N
Bone Marrow Transplant; 1994 Nov; 14(5):775-8. PubMed ID: 7889011
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome.
Zaja F; Russo D; Silvestri F; Fanin R; Damiani D; Infanti L; Salmaso F; Mariuzzi L; Di Loreto C; Baccarani M
Haematologica; 1997; 82(2):171-7. PubMed ID: 9175321
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
